Related Experiment Video

Updated: May 8, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Ibrutinib and novel BTK inhibitors in clinical development

Akintunde Akinleye1, Yamei Chen, Nikhil Mukhi

  • 1Division of Hematology/Oncology, Department of Medicine, New York Medical College, Valhalla, New York 10595, USA.

Journal of Hematology & Oncology
|August 21, 2013
PubMed

Insights

Bruton's tyrosine kinase (BTK) inhibitors, like ibrutinib, show promise for treating B-cell malignancies and autoimmune disorders. Further research is needed to optimize BTK inhibitor therapy and patient selection.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Targeting dysregulated signaling pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) has improved cancer treatment outcomes.
  • Bruton's tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling, is a new therapeutic target for cancers and autoimmune diseases.

Purpose of the Study:

  • To review the preclinical and clinical development of ibrutinib and other novel BTK inhibitors.
  • To highlight the therapeutic potential of BTK inhibition in B-cell malignancies and autoimmune disorders.

Main Methods:

  • Review of preclinical data on BTK inhibitors.
  • Analysis of early and phase III clinical trial results for ibrutinib.
  • Summary of development for other BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292, ONO-4059, CNX-774, LFM-A13).

Main Results:

  • Ibrutinib, a first-in-human BTK inhibitor, has shown clinical effectiveness and tolerability in trials.
  • BTK inhibitors are emerging as promising agents for B-cell malignancies and autoimmune conditions.

Conclusions:

  • BTK inhibition represents a significant advancement in treating B-cell malignancies and autoimmune disorders.
  • Further research is essential to determine optimal dosing and patient selection for BTK inhibitor therapy.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...